BCI and FES for Hand Therapy in Spinal Cord Injury

December 17, 2020 updated by: NHS Greater Glasgow and Clyde

Brain Computer Interface Control of Functional Electrical Stimulation for a Hand Therapy in Tetraplegic Patients

This study will assess whether functional recovery of the hand muscles in patients with spinal cord injury is enhanced when electrical stimulation of the muscles is delivered actively by means of using the electroencephalography wave patterns arising from the patient imagining moving their hand to operate the stimulator. A control group will obtain the electrical stimulation treatment passively by a therapist operating the machine.

Study Overview

Status

Completed

Conditions

Detailed Description

Injuries of the higher levels of the spinal cord, called tetraplegia, result in a complete or partial paralysis of both legs and arms, making the person dependent on their caregivers for elementary activities of daily living (ADL) such as drinking and feeding. About 60% of tetraplegics have an incomplete injury and can partially recover their movement and sensation. The success of a recovery greatly depends on the therapy within the first year after the injury. Functional electrical stimulation (FES) is a relatively novel therapy of the hand. In FES therapy electrodes are attached on the surface the patients's forearms and electrical current is delivered through them. A disadvantage of the current FES therapy is that a therapist has to switch the stimulator on and off because patients cannot use either of their hands. In our previous pilot study performed on two acute tetraplegic patients we tested feasibility of using brain-computer interface (BCI) to control FES on patient's will. BCI is based on recording the patient's brain activity. BCI can detect the patient's intention to move the hand even if they are not able to physically move it. Using BCI, patients control the FES by thinking to move their hand.

A BCI-FES therapy will provide a simultaneous training of neural pathways from the brain to the hand muscle (motor imagination/attempt) and from the muscle to the brain (electrical stimulation of muscles). This form of therapy could promote faster and more complete recovery

In this controlled study we aim to provide a BCI-FES therapy to both chronic and subacute tetraplegic patients over a period of 20 sessions and to access the functional and neurological outcome of the therapy. Five chronic patients (more than a year after the injury) will participate in a cross-over study as we do not expect that they will recover spontaneously without BCI-FES. Subacute patients will be receiving both a conventional therapy and BCI-FES so recovery can be caused by either of these two therapies. Therefore it is necessary to have a treatment and a control group. Each group will have 10 patients, age and injury matched. Both groups will receive the same amount of electrical stimulation but only the treatment group will voluntarily control the electrical stimulator using BCI. A control group will receive passive electrical stimulation of the same hand muscles but without using BCI.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Glasgow, United Kingdom
        • Queen Elizabeth National Spinal Injuries Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • incomplete (ASIA B, C) tetraplegia with injury at level C4-C8
  • aged between 18 and 70 years old
  • a candidate suitable for the conventional therapy

Exclusion Criteria:

  • Patients must not have presence of any neurological problem that might distort recording standard brain signal during motor imagination (example: brain damage, epilepsy, Parkinson disease and multiple sclerosis)
  • Patients must not have cognitive impairments (hearing, vision and general inability to understand instructions)
  • Patients must not suffer from recurring pressure sore which prevent patient from sitting for at least an hour
  • Patients must not suffer from excessive spasm that would increase with electrical stimulation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Active muscle stimulation
Muscle stimulation delivered by Brain Computer Interface
Brain computer Interface delivered Function Electrical Stimulation
Active Comparator: Passive muscle stimulation
FES will be delivered by therapist
Functional Electrical stimulation delivered by therapist

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Muscle strength as measured by the Oxford manual test
Time Frame: Between initial and final assessment after up to 8 weeks of treatment
Between initial and final assessment after up to 8 weeks of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in patients EEG before and after each treatment session
Time Frame: between beginning and end of each one hour treatment session
Measures will be taken at the beginning and end of each of the 20 treatment sessions
between beginning and end of each one hour treatment session
Difference in EEG between the treatment and the control group
Time Frame: Between initial and final assessment after up to 8 weeks of treatment
Between initial and final assessment after up to 8 weeks of treatment
Difference in Somatosensory evoked potential between the treatment and control group
Time Frame: Between initial and final assessment after up to 8 weeks of treatment
Between initial and final assessment after up to 8 weeks of treatment
Difference in somatosensory evoked potential before and after a treatment session
Time Frame: Between initial and final assessment after up to 8 weeks of treatment
Between initial and final assessment after up to 8 weeks of treatment
Patient's experience of using BCI-FES
Time Frame: Between initial and final assessment after up to 8 weeks of treatment
A questionnaire will collect information
Between initial and final assessment after up to 8 weeks of treatment
Quadriplegia index of function
Time Frame: Between initial and final assessment after up to 8 weeks of treatment
Between initial and final assessment after up to 8 weeks of treatment
Range of movement of wrists and fingers
Time Frame: Between initial and final assessment after up to 8 weeks of treatment
Between initial and final assessment after up to 8 weeks of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Aleksandra Vuckovic, PhD, University of Glasgow

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 8, 2013

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

April 30, 2013

First Submitted That Met QC Criteria

May 8, 2013

First Posted (Estimate)

May 13, 2013

Study Record Updates

Last Update Posted (Actual)

December 19, 2020

Last Update Submitted That Met QC Criteria

December 17, 2020

Last Verified

December 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spinal Cord Injury

Clinical Trials on BCI-FES

Subscribe